NEUP

Neuphoria Therapeutics Inc. Common Stock

NEUP

Market cap $19M

Overview Fund Activity

10.08 USD

-0.55

5.17%

At close Updated Sep 18, 11:22 AM EDT

1 day

-5.17%

5 days

-28%

1 month

29.4%

3 months

52.27%

6 months

105.71%

Year to date

244.03%

1 year

30.91%

5 years

-94.3%

10 years

-94.3%

About: Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

Employees: 24

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

35% more capital invested

Capital invested by funds: $935K [Q1] → $1.26M (+$328K) [Q2]

29% more funds holding

Funds holding: 7 [Q1] → 9 (+2) [Q2]

0.2% more ownership

Funds ownership: 9.27% [Q1] → 9.47% (+0.2%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$21

108% upside

Avg. target

$28

178% upside

High target

$35

247% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Maxim Group Jason McCarthy	$35	Buy Maintained	11 Sep 2025
HC Wainwright & Co. Joseph Pantginis	$21	Buy Reiterated	26 Aug 2025

See Analyst Rankings

Financial journalist opinion

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210 as a first-in-class, acute, “as needed”, fast-acting treatment for social anxiety disorder (SAD).

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced an upcoming presentation at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting.

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

Neuphoria Provides First Quarter 2025 Business Updates

BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provides business updates for the First Quarter of 2025.

Neuphoria Provides First Quarter 2025 Business Updates

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company's pipeline diversification beyond BNC210 US $15M milestone payment from Merck extends company's cash runway to Q3 2026 Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder (SAD) is progressing as planned with topline readout anticipated in Q3 2025 A Phase 2b dose ranging study with a lower dose of BNC210 in post-traumatic stress disorder (PTSD) is planned to follow the read-out of the Phase 3 study in social anxiety disorder SAD. BURLINGTON, Mass.

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients' lives, announced today that it will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York City on Monday, March 3rd, 2025.

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Zacks Investment Research

Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Neuphoria Therapeutics Inc. (NEUP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangement in relation to Bionomics Limited's proposed re-domiciliation from Australia to the United States, under which Neuphoria will become the ultimate parent company of Bionomics Limited, has been implemented today, December 23, 2024 New York time (December 24, 2024 Sydney time).

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

See News Rankings

Charts implemented using Lightweight Charts™